Adagio Medical closes $19M private placement to fund VT ablation device and FDA submission

Adagio Medical Holdings, Inc.

Closed $19M upfront private placement led by existing and new healthcare institutional investors.
Proceeds to support FULCRUM-VT pivotal study PMA submission for vCLAS ULTC System and next-gen catheter.
Will expand manufacturing, scale commercial-readiness, and extend cash runway into key inflection points.
Over 350 patients treated across regulatory studies, commercial, and compassionate use.
CEO states financing de-risks execution and provides flexibility to advance ULTC therapies for VT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.